Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RENX.LSE
- Price
- 6.25
- Stock movement up
- +- (0.00%)
- Company name
- Renalytix AI plc
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Health Information Services
- Market cap
- 27.31M
- Ent value
- 30.91M
- Price/Sales
- 11.52
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -33.84%
- 1 year return
- -34.21%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
RENX.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.52 |
| Price to Book | - |
| EV to Sales | 13.03 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 437.02M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.21M |
| Net receivables | 510.00K |
| Total current assets | 11.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 187.00K |
| Total assets | 11.44M |
| Accounts payable | 4.61M |
| Short/Current long term debt | 8.21M |
| Total current liabilities | 4.61M |
| Total liabilities | 12.81M |
| Shareholder's equity | -1.37M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.25 |
| Daily high | 6.50 |
| Daily low | 6.20 |
| Daily Volume | 64K |
| All-time high | 12.50 |
| 1y analyst estimate | 88.00 |
| Beta | 1.84 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 16 Mar 2026 |
Downside potential
Loading...
Downside potential data
| RENX.LSE | S&P500 | |
| Current price drop from All-time high | -50.00% | -1.08% |
| Highest price drop | -54.00% | -19.00% |
| Date of highest drop | 26 Aug 2025 | 8 Apr 2025 |
| Avg drop from high | -27.76% | -2.64% |
| Avg time to new high | 11 days | 6 days |
| Max time to new high | 240 days | 89 days |
COMPANY DETAILS
Marketcap
27.31M
Marketcap category
Small-cap
Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found